Navigation Links
Organogenesis, Life Sciences Center Break Ground on World's Largest Automated Living Cell Manufacturing Plant

CANTON, Mass., April 13, 2011 /PRNewswire/ -- Today Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister joined state and local officials,  Organogenesis, Inc. President & CEO Geoff MacKay and employees to celebrate the start of construction of 275 Dan Road.  Upon completion in 2013, the company expects the facility to be the world's largest automated living cell manufacturing plant.  

Organogenesis is in the midst of a major, multi-year expansion of its global headquarters, R&D and manufacturing facilities in Canton, Mass.

Organogenesis kicked off the celebration by announcing that it has selected Cambridge-based SMMA/Symmes Maini & McKee Associates as the architect and CRB Consulting Engineers, Inc. as the engineer for the state-of-the-art regenerative medicine manufacturing plant.  The company will use advanced robotic and modular manufacturing technologies within this planned facility, which will allow the company to leverage its leadership in the regenerative medicine field to attract substantial resources and jobs to Massachusetts over the next ten years.

The company also announced the purchase of 65 Dan Road in Canton, Mass. Approximately 30 percent of the 78,000 square foot building will be utilized for warehousing/storage with additional space to accommodate the company's rapid growth.  The acquisition of 65 Dan Road brings the company's total headquarters size to four buildings, comprising 330,000 square feet of space.

"This is an exciting day both for Organogenesis and for the Commonwealth," said Governor Deval Patrick. "Massachusetts will soon be home to a landmark manufacturing facility that will produce living technology that advances healing around the world, while at the same time creating jobs and expansion here at home. This is just the sort of innovation and job creation that our Life Sciences Initiative was designed to encourage."

"We are pleased to see Organogenesis continue to expand here in the Commonwealth," said Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center.  "This is a great example of the Life Sciences Initiative at work.  The regenerative medicine industry was born here, in our state's universities and labs, and we're thrilled to witness this burgeoning industry thriving and creating jobs."

"Today we're honored to have so many state and local officials join us to commemorate the start of construction of this state-of-the-art facility," said Organogenesis President & CEO Geoff MacKay.  "This is a huge milestone for Organogenesis, as well as for the Commonwealth and for the regenerative medicine industry as a whole.  We're growing in Massachusetts in size, in revenue and capacity; and in order to keep pace with our rapid growth, we're hiring across all departments."

Organogenesis is in the midst of a major, multi-year expansion of its global headquarters, R&D and manufacturing facilities.  The company estimates its total investment in the two-phased expansion will be approximately $63 million.  

The Life Sciences Center, charged with implementing the State's ten-year, $1 billion Life Sciences Initiative that was signed into law by Governor Patrick in June of 2008, awarded a $7.4 million grant to Organogenesis, Inc. to help facilitate the expansion.  The Center provided $3.7 million in FY 2009 and $3.7 million during FY 2010.  

The Massachusetts Office of Business Development worked closely with Organogenesis to create a $12.9 million incentive package, including the Life Sciences Center grant, as well as tax credits for research-and-development expansion.  In addition, the State facilitated $5 million in low-interest loans for growth initiatives.  The Life Sciences Initiative also addressed tax inequalities when compared with competing states.  

As part of the agreement, Organogenesis committed to creating 280 new in-state jobs by 2013, and specifically to creating 17 new in-state jobs in 2011.  In the first quarter of 2011, the company surpassed its target expectations for 2011 Massachusetts job creation by adding 19 in-state jobs, with an additional 35 open positions.

About SMMA

SMMA / Symmes Maini & McKee Associates is an award-winning, integrated design firm offering architecture, engineering, planning, and interior design services to corporate, commercial, technology, life science, healthcare, and institutional clients. Founded in 1955, SMMA is a company of 180 professionals with offices in Cambridge, MA and Providence, RI.

About CRB

CRB is a leading solutions provider serving primarily the life science industry such as pharmaceutical, biotechnology, specialty chemical and higher education.  Services include mechanical, electrical, process, process simulation, instrumentation and automation, architectural, and commissioning.  CRB delivers in all areas of project execution, from strategic planning and initial project programming, through conceptual and detailed design and into construction and commissioning.  Established in 1984, CRB has grown to a staff of over 365 with offices in Boston, Kansas City, St. Louis, Raleigh, Philadelphia, San Diego, San Jose, Kalamazoo, Boulder and San Juan.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center ("the Center") is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition.  This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit

About Organogenesis, Inc.

Having pioneered the field, Massachusetts based Organogenesis, Inc. is a leading regenerative medicine company focused in the areas of bioactive wound healing, oral regeneration and biosurgery. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit  

SOURCE Organogenesis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Magellan Biosciences Announces Agreement with Bruker to Provide Microbiology Tools to Battle Drug Resistance
2. EMC Isilon Customers Discuss the Big Data Opportunity in Life Sciences at Bio-IT World Conference 2011
3. Magellan Biosciences and Miacom Diagnostics Team Up to Enable Faster, Easier Identification of Pathogens as Part of Magellans End-to-End Suite of Microbiology Products Designed to Streamline Lab Workflow and Enable Better Treatment Decisions
4. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
5. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
6. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
7. Advanced Life Sciences Announces 2010 Fourth Quarter and Full Year Financial Results and Reverse Stock Split
8. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
9. John W. Manzetti and the Pittsburgh Life Sciences Greenhouse Recognized as 2011 Outstanding Leader in Technology
10. Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):